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ABSTRACT 
Objectives: Challenges with patient-reported outcome (PRO) evidence and health state utility values 
(HSUVs) in rare diseases exist due to small, heterogeneous populations, lack of disease knowledge 
and early onset. To better incorporate quality of life (QoL) into Health Technology Assessment, a 
clearer understanding of these challenges is needed.  
Methods: NICE appraisals of non-oncology treatments with an EMA orphan designation (n=24), and 
corresponding appraisals in the Netherlands, France, and Germany were included. Document 
analysis of appraisal reports investigated how PROs/HSUVs influenced decision-making and was 
representative of QoL impact of condition and treatment. 
Results: PRO evidence was not included in 6/24 NICE appraisals. When included, it either failed to 
demonstrate change, capture domains important for patients, or was uncertain. In the other countries, 
little information was reported and evidence largely did not demonstrate change. In NICE appraisals, 
HSUVs were derived through the collection of EQ-5D data (7/24 cases), mapping (6/24), vignettes 
(5/24), and published literature or other techniques (6/24). The majority did not use data collected 
alongside clinical trials. Few measures demonstrated significant change due to lack of sensitivity or 
face validity, short-term data, or implausible health states. In 8/24 NICE appraisals, patient surveys or 
input during appraisal committee meetings supported the interpretation of uncertainty or provided 
evidence about QoL.  
Conclusions: This study sheds light on the nature of PRO evidence in rare diseases and associated 
challenges. Results emphasise the need for improved development and use of PRO/HSUVs. Other 
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Rare diseases are conditions affecting a small number of patients (e.g. less than 1/2,000 people in 
Europe), which are life-threatening and/or chronically debilitating, frequently genetic and with an early 
onset [1, 2]. Quality of life (QoL) of patients living with a rare disease is often poor due to multiple 
aspects affecting functioning [3]. This is partly explained by issues around diagnostic delays, and/or a 
lack of knowledge about the disease, its treatment pathways or treatment options [3]. Given the 
severity of these conditions and paucity of curative treatments, understanding their impact on QoL is 
crucial, particularly when assessing the benefit of a new treatment.  
Health Technology Assessment (HTA) aims to assess the value of a treatment to inform decisions on 
whether it should be provided routinely to the relevant patient population. The assessment generally 
relies on clinical and patient-reported outcome (PRO) endpoints, which provide evidence about health 
outcomes and impact on patients’ wellbeing [4].  In the latter case, PRO evidence is collected directly 
from patients or proxies using patient-reported outcome measures (PROMs) [5].  PROMs are 
intended to capture aspects that matter most to patients about the impact of disease and treatment on 
symptoms, QoL or health status [6].  
HTA relies on the critical assessment of added benefit or cost-effectiveness of a treatment. This is 
then appraised by a Committee, taking account of other relevant factors, who decide on 
reimbursement (and pricing in some cases). Added benefit is assessed by considering the magnitude 
and certainty of treatment benefit over existing therapies based on the clinical and PRO evidence 
presented. The level of benefit is then generally ranked into categories as, for example, in France, 
where the added benefit (ASMR) is ranked between I and V. In cost-effectiveness assessments, an 
economic evaluation is conducted that models the progression through health states along the care 
pathway, with and without the new treatment under review. In order to assist cost-effectiveness 
assessments, techniques have been developed to translate PRO evidence into numerical values 
called health state utility values (HSUVs). HSUVs represent individual preferences for given health 
states measured on a scale between 0, representing dead and 1, full health (with negative values 
implying states considered to be worse than dead). These are then merged with survival data (e.g., 
length of life) into a composite measure called quality-adjusted life-year (QALY). HSUVs represent the 
utility value associated with the different models’ health states, for both treatment and comparator 
arms [7]. The most common way of deriving HSUVs is currently using indirect techniques, e.g. 
preference-based instruments such as EQ-5D that are accompanied by an algorithm (or a set of 
tariffs) providing HSUVs. Tariffs are pre-determined at individual country level by a sample of the 
general population that uses direct techniques (e.g. time trade-off) to express preferences for a 
subset of health states derived from the combination of instrument’s dimensions and levels. 
Challenges exist when developing and using PRO evidence and HSUVs for HTAs of rare diseases 
treatments due to the small and heterogeneous nature of the patient populations, and frequent lack of 
knowledge about the disease [8, 9]. Additionally, patients are often children or infants who cannot 
self-report and who may be cognitively impaired or unable to communicate. There may also be 
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distinct challenges around capturing meaningful outcomes, including: difficulty achieving concept 
validity through concept saturation, use of methods that may not capture aspects important for 
patients, or selecting the appropriate PROM when natural history is poorly understood. There are also 
few validated disease-specific PROMs for rare diseases, probably due to the amount of time and 
resources needed to develop these instruments, which are further complicated by the nature of these 
diseases [10].  
Additional challenges frequently encountered when deriving and using HSUVs for rare diseases 
include the need for a large number of respondents to minimise random measurement errors (e.g. 
person-trade-off, development of mapping algorithms), identification of appropriate values 
corresponding to the model’s health states from the existing literature, and QALYs being insufficiently 
sensitive to disease severity or changes that are important for patients [11–14]. 
Although these challenges in measuring QoL are common to all rare disease treatments, they are 
most important in treatments of non-oncological diseases, since in cancer the main value of treatment 
is often increased survival, and many rare disease treatments in cancer are for sub-populations of a 
more common cancer for which validated QoL measures may be available. 
To better incorporate QoL evidence into HTA decision-making, a clearer understanding of the 
challenges encountered when using PRO evidence and HSUVs in rare diseases is needed. Hence 
this research explored how QoL evidence has been used in appraisal of non-oncology rare disease 




For this EU Horizon2020 project, European countries were selected to represent those that make 
decisions based on added clinical benefit and those that focus on cost-effectiveness, and who have 
publicly available reports. Those selected were England (National Institute for Health and Care 
Excellence, NICE) and the Netherlands (National Health Care Institute, ZIN) as users of the cost-
effectiveness approach, and France (Haute Autorité de Santé, HAS) and Germany (Federal Joint 
Committee, G-BA) as users of the added benefit approach. Considering the depth of the analysis 
conducted, the inclusion of four countries was considered sufficient to understand the nuances 
between one HTA approach and another, and the types of contrasts within one approach.  As only the 
reports from NICE presented detailed information about the committee deliberations of the QoL 
evidence, the analysis focused on the NICE appraisals, and other countries’ appraisals were used as 
a contrast to highlight any different approaches. 
All treatments with a European Medicines Agency (EMA) orphan medicinal product designation and 
appraised by NICE within its Technology Appraisal (TA) or Highly Specialised Technologies (HST) 
programmes before 1 June 2020 were selected (n=50). Cancer treatments (26) were excluded 
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because added benefit often relies on survival gains, and many rare cancers are subsets of more 
common cancers for which a validated PRO often exists [4, 15].  This left 24 rare disease treatments 
(12 TA and 12 HST) for analysis [16, 17, 26–35, 18, 36–39, 19–25] In the results section, the 
information reported for the individual NICE sample was extracted from these reports.  
Data collection and analysis 
Information about QoL, PROs, HSUVs and other evidence from patients about their QoL (such as 
patient group submissions and patient expert input) was extracted from NICE’s appraisal reports. 
These were sufficiently detailed to enable documentation of the source of the evidence, results, 
issues highlighted by the appraisal committee and the influence on the decision. If needed, supporting 
documentation such as manufacturer submissions and Evidence Review Group (ERG) reports were 
reviewed. A published framework was used to extract these key aspects of the appraisal in a 
structured way [40]. PRO evidence was categorised on the basis of the type of PROM used (generic, 
disease-group (developed for a range of conditions), disease-specific or symptom-specific). HSUVs 
were categorised on the basis of the technique used to derive them (e.g. collection using an 
instrument such as EQ-5D, or mapping from other PROMs).  
Thematic analysis was undertaken to identify issues arising in appraisals and their influence on 
decision-making based on the researchers’ interpretation of the discussion reported in the published 
documents. The identification of themes was done iteratively and was continuously refined while the 
researchers familiarised themselves with the data and grouped the data in a logical way to allow for a 
better understanding of the decision process [41]. Once the themes were identified and categorised, 
the researchers assessed the level of influence of PRO evidence or patient evidence on decisions. 
This was categorised as “influence” when the Committee explicitly recognised and accounted for a 
change in QoL in their decisions, “possible influence” when PRO evidence or patient evidence was 
explicitly reported but considered limited by the Committee and it was therefore unclear whether it 
influenced the decision, and “no influence” when PRO evidence or patient evidence was reported, but 
inconclusive or failed to demonstrate change and did not influence the Committee’s decision. HSUVs 
were considered in all cases to have influence on the decision, since the Committee always took note 
of the incremental cost per QALY ratio. The interpretation of the HSUV evidence was distinguished as 
“accepted” when the Committee recognised the evidence presented was acceptable, “not 
commented” when no issues were raised with the HSUVs presented and therefore there was a high 
likelihood that it was accepted, and “uncertain” when a number of issues around the HSUV were 
highlighted, which rendered their interpretation challenging.  
The second set of extracted information related to the burden of disease and treatment impact: 
infant/childhood onset; progressive; heterogeneous; multi-systemic; debilitating; life-threatening; 
supportive care; and regarding the impact of treatment on QoL: length of life improved, QoL improved 
from reduced symptoms, daily living, families/carers, compared to current treatment, administration 
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mode. The burden of disease and intended impact of the treatments reported in the HST and TA 
programmes, respectively, were extracted and compared.  
The analysis aimed to understand how QoL was appraised, and the extent to which PRO evidence 
and/or HSUVs were considered appropriate. The possible influence of the nature of the rare diseases 
on PRO evidence and HSUV estimates was also explored to generate a better understanding of what 
was feasible in the different contexts.  In the cross-country analysis, the information reported by the 
other countries was scarce. The focus was therefore on the PRO evidence and HSUVs considered 
and their influence on the decision.  
Results 
Impact of disease and treatment on quality of life  
Most of the diseases undergoing the TA and HST processes were life-threatening and/or debilitating 
(Figure 1). The burden of disease, however, was greater in the diseases undergoing the HST 
programme compared with the TA in that these diseases affect children, have a heterogeneous and 
progressive nature, or affect multiple organs. With the exception of the prophylaxis treatment 
letermovir, the symptoms of all of the diseases analysed affect patients’ daily living and QoL.  No 
previous treatments were available for 58% (7/12) and 17% (2/12) of those undergoing the HST and 
TA processes, respectively.  
In terms of the intended effects of treatment, 67% (8/12) of HST and 83% (10/12) of TA treatments 
aim to improve length of life, while all improve patients’ daily living and QoL by reducing symptoms 
(with the exception of letermovir).  Six of these aim solely to improve QoL. Furthermore, all of the HST 
and 83% (10/12) of the TA treatments aim to improve patients’ daily living and QoL over standard of 
care. In 50% of all cases (12/24), QoL improvement is linked to a different administration mode. 
All conditions appraised by HST and half of those by TA were considered to affect carer QoL. In all 
cases, with the exception of letermovir, the treatment intends to improve their QoL.   
The estimated yearly number of patients to be treated in England ranged between 1-50 for 10 of the 
12 HST treatments [1-7 patients for 3 treatments, 20-35 for 2 treatments, 50-100 for 3 treatments, and 
140-150 for 2 treatments]. No details about patient numbers were provided in all other cases. 
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Figure 1. Proportion of appraisals for which various items of burden of disease and treatment impact 
are relevant in NICE Highly Specialised Technology and Technology Appraisal programmes (n=24) 
 
Use and influence of PRO evidence in NICE appraisals  
In NICE appraisals, PROMs can have an influence either through being considered directly and/or 
through their use in generating HSUVs. Across the 24 treatments appraised by NICE, 28 different 
PROMs were reported. This included 10 generic PROMs considered across 14 treatments, seven 
disease-group PROMs across seven treatments, three disease-specific PROMs across five 
treatments, and eight symptom-specific PROMs across seven treatments (Table 1). Several PROMs 
could considered for the same treatments. Examples of disease-group PROMs include the Paediatric 
Outcomes Data Collection Instrument (PDOCI) measuring functional outcomes in paediatric 
orthopedics [42], and the St George's Respiratory Questionnaire (SGRQ) measuring overall health, 
daily life, and perceived well-being in patients with obstructive airways disease [43]. The three 
disease-specific PROMs considered were for cystic fibrosis (Cystic Fibrosis Questionnaire Revised 
questionnaire, CFQ-R), recurrent angioedema (Angioedema Quality of Life questionnaire, AE-QoL), 
and neuronal ceroid lipofuscinosis type 2 (Neuronal Ceroid Lipofuscinosis Type 2 Quality of Life 
Instrument, CLN2-QoL). The seven symptom-specific PROMs related to pain, gastro-intestinal 
symptoms, diabetic neuropathy, fatigue, asthma, and anxiety and depression (Table 2).  
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Forty-two percent (10/24) of submissions did not include any generic PRO, and 25% (6/24) no PRO 
evidence at all. Reasons for the latter included PRO evidence not collected in trials (elosulfase alfa, 
obetocholic acid, holoclar), collected but limited (strimvelis), being collected and not reported 
(burosumab), or not presented given it was a re-assessment based on new clinical evidence 
(pirfenidone). In two of the cases without PRO evidence, other QoL evidence was considered, such 
as observational studies and cross-sectional surveys involving patients and families (elosulfase alfa), 
and visual acuity data from the literature used to derive HSUVs (holoclar) (Table 1). QoL evidence for 
the remaining drugs without PRO data was based on HSUVs derived from vignettes or published 
evidence (Table 3, discussed in the next section on HSUVs). 
Table 1. Types and influence of PRO evidence considered in NICE TA and HST appraisals of non-
oncology rare disease treatments (n=24) 
 
  
PRO data considered in NICE appraisals 





































Asfotase alfa ++ NR 
   
Eculizumab HSUV    +++ 
Patisiran HSUV   +++ +++ 
Voretigene  NR    
Cerliponase ++  ++   
Elosulfase alfa*      +++ 
Ataluren ++ ++    
Migalastat ≈   ≈ +++ 
Eliglustat HSUV   ++ +++ 
Strimvelis**      





















Inotersen    ≈  






[=antibiotics]   HSUV  +++ 
Nintedanib HSUV NR  NR ++ 
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Lumacaftor–ivacaftor HSUV  ++   
Mepolizumab HSUV HSUV  NR  
Obeticholic acid**      
Holoclar *      
Pirfenidone***      
Darvadstrocel  NR   
Nusinersen HSUV     
Letermovir ≈ ≈   +++ 
Lanadelumab ≈  ≈ NR  
 
Legend: HSUV: Health State Utility Value; NICE: National Institute for Health and Care 
Excellent; PRO: Patient Reported Outcome; PROM: Patient Reported Outcome Measure  
*No PRO data was provided, but patient based evidence or PRO data from the literature was 
used instead 
** No PRO data was provided, QoL evidence was derived from HSUVs from vignettes or 
published literature  
*** No PRO data was included in the appraisal report as this is a re-assessment and no new 
QoL evidence was presented 
+++ Influence – PRO results / patient evidence were influential in the final decision 
++ Possible influence - PRO results / patient evidence were reported and suggested 
some type of benefit, but no discussion about these results was reported  
≈ No influence - PRO results were reported, but did not show any benefit and no 
discussion about these results was reported  
NR Not reported / no influence - PRO results not reported, but the report listed the 
PROM as having been collected 
HSUV  
 
Used to derive HSUVs – PRO results was used to derive HSUVs (further discussed in 
Table X) 




Table 2. Use and influence of PRO evidence in NICE TA and HST appraisals of non-oncology rare disease treatments (n=24) 
 
MEDICINE 
Generic name - indication 
PROM (by type) 
Instrument (source) 
PRO EVIDENCE 
Description of results 
APPRAISAL 
Influence of PRO evidence on decision 
Asfotase alfa  
Paediatric-onset 
hypophosphatasia 
G - EQ-5D (EU patient 
survey) 
 
G - CHAQ, LEFS (small 
trials) 
EQ-5D 
- children 0.76 treatment arms 0.43 no 
treatment 
- adults 0.39 no treatment 
- scores varied depending on walking ability [-
0.24 to 0.73 in children, -0.01 to 0.51 in adults] 
 
Other trial PRO data in academic confidence 
EQ-5D results not used to derive HSUVs but 
may have been considered by clinicians 
when developing the vignette's health states 
based on 6MWT severity levels. Specifically, 
mental health and pain domains 
Eculizumab  
Atypical haemolytic uraemic 
syndrome (aHUS) 
G - EQ-5D (2 phase II 
prospective, open-label, 
non-randomised, single 
arm trials, n=37) 
 
P - Survey (patient 
submission, n=37) 
EQ-5D: mean improvement = 0.208 
 
Survey: burden of disease and of current 
treatment on patients, carers/families 
EQ-5D used to derive HSUVs.  Survey shows 
greatly impaired QoL of patients and carers 




G - EQ-5D-5L (RCT, 
n=255) 
 
D - NIS, Norfolk-DN 
(RCT, n=255) 
 
P - Patient and clinical 
input 
All PRO evidence significantly improved. NIS 
was trial's primary endpoint 
 
Patient input: factors not captured in model 
important for patients, e.g. ability to walk 
EQ-5D-5L used to derive HSUVs. Effective 
based on significantly improved outcomes. 
PRO evidence captures most relevant 
treatment impacts, except for ability to return 
to work, daily activities, social life, impact on 
carers and families.  Higher ICER accepted 
given effect size and aspects not captured. 





Generic name - indication 
PROM (by type) 
Instrument (source) 
PRO EVIDENCE 
Description of results 
APPRAISAL 
Influence of PRO evidence on decision 
Voretigene  
Inherited retinal dystrophies 
D - VFQ (patient survey) Results not reported as confidential The committee highlighted preference for 
QoL collected from trials  
Cerliponase  
Nuronal ceroid lipofuscinosis 
type 2 
G - EQ-5D 5L, PedsQL, 
PedsQL-FM (pivotal trial, 
single-arm, open-label, 
n=23, children 3-16 
years) 
 
D - CLN2-QoL (pivotal 
trial) 
QoL evidence: improvement in initial treatment 
phase (only short term data) 
Recognition of limited QoL evidence due to 
short term data. Unclear if PRO data 




P - Cross-sectional 
survey from patient and 
family, company 
submission, 63 patients 
+ 56 families 
 
O - Observational study 
on natural history (n = 
325 people, up to 10 
years)  
No PROMs collected in trials 
 
Survey: QoL impact related to reliance on 
wheelchair, endurance, pulmonary function and 
height. Impact on carers up to 15 hours/day 
 
Observational study: decline in endurance, 
restricted growth, limitations in daily living 
Survey used to derive HSUVs 
 
Observational study: supported interpretation 
of impact on QoL and HSUVs, including 
aspects not captured in HSUV 





Generic name - indication 
PROM (by type) 
Instrument (source) 
PRO EVIDENCE 
Description of results 
APPRAISAL 




G - PedsQL (phase IIb) 
 
G - PODCI, ADLQ (RCT, 
confirmatory trial) 
 
P - Survey of carers 
(company submission) 
PRO results not reported. PODCI, ADLQ 
confidential 
 
Survey: impact on multiple aspects of life, e.g. 
emotional wellbeing, mental health, personal 
care, ability to maintain relationships. 
Caregivers felt tired, depressed, anxious. In 
many cases, at least another family member in 
addition to both parents were involved in giving 
care (for example, siblings and grandparents) 
QoL data (all): underestimate due to short 
trial duration (48 weeks too short to capture 
impact on ability to walk) 
 
PedsQL: results not aligned with patient 
statements on meaningful stabilisation or 
improvement in walking, or ability to conduct 
daily activities 
 
Survey: unclear influence , possibly 
considered in estimating extent of impact on 
caregivers, but not reported 
Migalastat  
Fabry disease 




(ATTRACT) and RCT 
(FACETS)) 
 
D - BPI, GSRS 
(ATTRACT, FACETS) 
 
P - Patient and clinical 
input (oral administration) 
QoL data: inconclusive (no change), except for 
change in GSRS  
 
Input: benefits of oral administration 
Patient input confirmed benefit of oral 
administration over infusion 
 
PRO data not discussed in report, nor used 
to derive HSUVs 





Generic name - indication 
PROM (by type) 
Instrument (source) 
PRO EVIDENCE 
Description of results 
APPRAISAL 
Influence of PRO evidence on decision 
Eliglustat  
Gaucher disease 
G - SF-36 general health, 
physical and mental 
components  (open-label 
trial (ENCORE) and RCT 
(ENGAGE)) 
 
D - FSS, BPI (ENCORE 
and ENGAGE) 
 
P - Patient survey and 
patient submission (oral 
administration)  
QoL: maintained with treatment 
 
FSS: fatigue > placebo (not statistically 
significant) 
 
SF-36, BPI: no change  
 
Patient input: preference for oral administration 
SF-36 used to derive HSUV 
 
Unclear influence of PRO evidence. Adverse 
event HSUVs included, not clear if influenced 
by FSS or BPI 
 
Advantage of oral administration as key 





None No QoL evidence presented. Data being 
collected within trial (not reported) 
Not reported 
Burosumab for X-linked 
hypophosphataemia 
None No QoL evidence presented. Data being 





 D – Norfolk QoL-DN 
(RCT) 
Norfolk QoL-DN: no change in treatment arm, 
decrease in placebo arm 
Not reported 





Generic name - indication 
PROM (by type) 
Instrument (source) 
PRO EVIDENCE 
Description of results 
APPRAISAL 
Influence of PRO evidence on decision 
Mannitol for cystic fibrosis G - HUI2 (RCT, trial 301) 
 
D - CFQ-R (RCT, trial 
302) 
HUI2: no significant change 
 
CFQ-R: no significant change, improvement in 
respiratory, physical and vitality domains, but 
not significant 
HUI2 used to derive HSUVs.   
 
No ideal measures to capture the QoL 
impact, including adverse events from current 
treatments, e.g. unpleasant taste or 
sensations, as reported by patients 
Colistimethate sodium and 
tobramycin dry powders for 
inhalation (DPI) [=antibiotics]  
Pseudomas lung infection in 
cystic fibrosis 
D - CFQ-R (open-label 
RCT) 
 






P - Patient input 
Colistimethate sodium DPI 
CFQ-R from non-inferiority trial   
 
Tobramycin DPI 
No QoL data collected in trial, relied on 
treatment satisfaction questionnaire and patient 
input 
Colistimethate sodium DPI 
CFQ-R: no improvement since non-inferiority 
trial   
 
Tobramycin DPI 
Questionnaire: higher values for DPI over 
nebuliser  
 
Limited influence of QoL data on decision 
and interpretation of economic model. 
Recognition of improved speed and 
adherence with DPI based on patient input 
and questionnaire 
Nintedanib  
Idiopathic pulmonary fibrosis 
G - EQ-5D, PGI-C (RCT) 
 
D - SQRQ, SOBQ, 
CASA-Q  
 
P - Patient input 
(tolerability) 
PRO data: not reported  
 
Patient input: better tolerability profile impacting 
QoL, ability to go outdoors due to less photo 
sensibility 
EQ-5D used to derive HSUVs 





Generic name - indication 
PROM (by type) 
Instrument (source) 
PRO EVIDENCE 
Description of results 
APPRAISAL 
Influence of PRO evidence on decision 
Lumacaftor–ivacaftor 
Cystic fibrosis 




D - CFQ-R (TRAFFIC 
and TRANSPORT) 
EQ-5D: high baseline values due to patients 
perception of life as "normal", difficult to 
capture improved QoL (ceiling effect, common 
in cystic fibrosis). No significant difference 
[mean difference 0.0095 (TRAFFIC) and -
0.0009 (TRANSPORT)] 
 
CFQ-R: mean difference of 2.2 < 4 MID  
CFQ-R: other studies with similar severity 
levels showed greater changes compared to 
trial results 
 
EQ-5D: no evidence on reasons for being 
inappropriate. EQ-5D usually captures most 
important aspects in cystic fibrosis based on 
expert input 
Mepolizumab  
Severe refractory eosinophilic 
asthma 
G - EQ-5D (RCT 
DREAM) 
 
D - SGRQ, ASQ (RCTs 
MENA and SIRIUS) 
SGRQ: QoL increase due to fewer 
exacerbations AND improved symptom control 
and lung function 
EQ-5D used to derive HSUVs 
 
SGRQ: possible confounding (exacerbation 
reduction ~ fewer symptoms). Improved 
symptoms recognised (beyond those from 
fewer exacerbations). SGRQ also mapped to 
derive HSUVs 
Obeticholic acid for primary 
biliary cholangitis 
None No PRO data collected in trial   
Holoclar for limbal stem cell 
deficiency after eye burns 
None No PRO data collected in trial HSUVs derived from impact on visual acuity 





Generic name - indication 
PROM (by type) 
Instrument (source) 
PRO EVIDENCE 
Description of results 
APPRAISAL 
Influence of PRO evidence on decision 
Pirfenidone  
Idiopathic pulmonary fibrosis 
None Re-submission to extend indication to patients 
>80% FVC. Quality of life data not discussed 
(as did not change from initial submission, for 
which the report was no longer available) 
No PROMs reported, no impact on decision 
(apart from QoL data captured in model). 
Darvadstrocel  
Crohn’s disease 
D - PDAI (RCT ADMIRE) PDAI results not reported  PDAI does not capture QoL impact (only 
symptoms) => preference for EQ-5D trial 
data  
Nusinersen  
Spinal muscular atrophy 
G - PedsQL (RCT 
CHERISH) 
PedsQL results not reported in appraisal 
report, only in committee papers. Data kept 
confidential, likely due to the challenges to 
collect data from babies and children for SMA 
PedsQL mapped to EQ-5D 
Letermovir  
Cytomegalovirus 
G - EQ-5D (RCT PN001) 
 
D - FACT-BMT (PN001) 
 
P – Patient and clinical 
input (on QoL from 
preventing CMV) 
PN001 trial: not powered to show changes 
QoL, no improvements 
 
Results confounded by mix of patients who 
have had CMV reactivation and started pre-
emptive therapy and those who have not 
Trial limitations and challenges to capture 
change recognized 
 
Patient and clinical experts input on QoL 
impact from preventing CMV accounted for in 
decision (ICER likely to be lower due to this, 
which lead to a positive decision) 
Lanadelumab for hereditary 
angioedema 





EQ-5D-5L: no change due to lack of sensitivity 
in condition (timing of response - only two 
responses during attacks captured) 
 
AE-QoL: statistically improved 
 
EQ-5D-5L data used to derive HSUVs 
 
Other results not commented  





Generic name - indication 
PROM (by type) 
Instrument (source) 
PRO EVIDENCE 
Description of results 
APPRAISAL 
Influence of PRO evidence on decision 
D - AE-QoL, HADS 
(HELP-03 + 04) 
Other PROMs not reported in appraisal report 
or committee papers 
Legend: G: generic patient reported outcome measure; D: disease, disease-group or symptom-specific patient reported outcome measure; P: patient 
evidence; NA: no report available; MID: minimal important difference; CHAQ: childhood health assessment questionnaire; LEFS: lower extremity functional 
scale; NIS: neuropathy impairment score; Norfolk-DN: Norfolk quality of life-diabetic neuropathy; VFQ: visual function questionnaire; PedsQL: Paediatric 
Quality of Life Inventory - Parent Report for Toddlers; PedsQL-FM: PedsQL family impact module; CLN2-Qol: CLN2 quality of life instrument; PODCI: 
paediatric outcomes data collection instrument; ADLQ: activities of daily living questionnaire; FSS: fatigue severity scale; BPI: brief pain inventory; CFQ-R: 
cystic fibrosis questionnaire revised; HUI2: Health Utility Index Mark 2; SGRQ: St George Respiratory Questionnaire; SOBQ: University of California San 
Diego shortness of breath questionnaire; CASA-Q: cough and sputum assessment questionnaire; PGI-C: patient global impression of change; ASQ: asthma 
control questionnaire; PDAI: perianal disease activity index; FACT-BMT: functional assessment of cancer therapy; AE-QoL: angioedema quality of life 
questionnaire; WPAI:GH: work productivity and activity impairment questionnaire - general health; HADS: hospital anxiety and depression scale; EQ-5D-5L: 
EuroQol-5 Dimension-5 Level 
Sources: [16-39] 
 
Author Accepted Manuscript (30/09/2021) for the European Journal of Health Economics Published 




Further exploration of the influence of PRO evidence on NICE decisions suggested that beyond those 
used to derive HSUVs, few of them had any influence on the decisions (Tables 1 and 2).   
Of the 14 appraisals considering generic PRO evidence, eight were used to derive HSUVs and the 
remaining six had unclear or no influence on the decisions. For asfotase alpha, the EQ-5D data 
collected in a patient survey may have been considered by clinicians when developing the vignette’s 
health states, but it is not discussed in the report. For cerliponase, it was inconclusive due to the lack 
of correspondence between EQ-5D and the model’s health states, and short trial duration for the 
Pediatric Quality of Life Inventory (PedsQL). For ataluren, no significant improvements in the PedsQL 
were shown, despite the positive trend in the functioning subscale. For the remaining treatments 
(migalastat, letermovir, lanadelumab), the SF36 and EQ-5D collected did not show any significant 
improvements and were not considered. 
With the exception of one disease-group PROM used to derive the economic model’s HSUVs, their 
inclusion had limited influence. This was the case for mepolizumab, where SGRQ data, suggesting 
improved QoL due to fewer exacerbations and improved symptom control and lung function, was 
mapped to EQ-5D to obtain HSUVs. In the other cases, the PODCI data collected for ataluren 
showed improvements on two dimensions, but was considered uncertain due to the short trial 
duration. In all other cases (letermovir, asfotase alfa, voretigene, darvadstrocel and nintedanib), the 
disease-group PROMs, Functional Assessment of Cancer Therapy - Bone Marrow Transplantation 
(FACT-BMT), PODCI, Visual Function Questionnaire (VFQ), perianal disease activity index (PDAI), 
SGRQ or Shortness of Breath Questionnaire (SOBQ) either did not show a significant improvement or 
were not reported.  
A similar situation was seen for the disease-specific PROMs. For only one case, colistimethate 
sodium and tobramycin DPI, the CFQ-R was mapped to HSUVs and used for the decision. However, 
it did not show any improvement in QoL relating to administration mode (dry powders for inhalation 
versus nebuliser) given a non-inferiority trial design was adopted. For three treatments, the PRO 
evidence was uncertain and thus the influence on the decision was unclear. The data collection 
period of CLN2-QoL for cerliponase was considered too short, and the CFQ-R data collected for 
mannitol dry and lumacaftor-ivacaftor did not show a statistically significant improvement. Results 
from the AE-QoL data collected for lanadelumab were not commented on in the appraisal report. 
Of the six treatments that considered symptom-specific PROMs, one of them influenced and another 
possibly influenced the decision. For patisiran, the Neuropathy Impairment Score (NIS) and Norfolk 
Quality of Life Questionnaire - Diabetic Neuropathy (Norfolk QoL-DN) data collected was statistically 
improved and contributed to recognising treatment effectiveness. For eliglustat, no significant 
improvements were demonstrated for the Fatigue Severity Scale (FSS) and Brief Pain Inventory 
(BPI), and it was unclear whether they were used to determine the HSUV estimated to measure the 
impact of adverse events on QoL included in the submission. In the remaining cases, there was either 
no demonstration of change with BPI and Gastrointestinal Symptoms Rating Scale (GSRS) for 
migalastat and with Norfolk QoL-DN for inotersen, or results were not reported (Cough and Sputum 
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Assessment Questionnaire, CASA-Q for nintedanib, Asthma Control Questionnaire, ASQ for 
mepolizumab and Hospital Anxiety Depression Scale, HADS for lanadelumab). 
For eight of these drugs, determination of QoL impact was influenced by patient evidence (Table 2). 
First, patient surveys provided information about impact of QoL on patients and carers (eculizumab, 
ataluren), preferences for administration mode (eliglustat, colistimethate sodium and tobramycin DPI), 
or whether it was used to derive HSUVs (elosulfase alfa). Respondents were patients and in one case 
also family members, three formed part of the company submissions and the other two, patient 
submissions. Second, patients and clinicians provided input about the dimensions not captured in the 
model (patisiran), about impact on QoL (letermovir), effect on tolerability (nintedanib), and 
administration mode (migalastat, eliglustat, colistimethate sodium and tobramycin DPI). 
Use and influence of HSUV estimates in NICE appraisals  
The most frequently used technique to derive HSUVs in NICE appraisals was through EQ-5D data 
(7/23) collected within a trial (4/7) or from a registry or cohort study (3/7), followed by mapping (6/23), 
vignettes (5/23), published literature (3/23), Health Utility Index Mark 2 (HUI2) (1/23) and other (1/23) 
(Table 3). No HSUVs were reported for one treatment (pirfenidone) given it was a re-assessment; 
therefore, it was excluded from this analysis, which focused on the 23 remaining treatments. The 
mapping technique was more frequently used in the TA, and vignettes in the HST process. Additional 
HSUVs were derived to measure the impact on QoL of adverse events (9/23), of the administration 
mode (4/23), of carer burden (7/23) or other (7/23) and considered alongside the HSUV derived.  
Table 3. Techniques used to derive HSUVs in NICE TA and HST appraisals of non-oncology rare 
disease treatments (n=23)  
  
Techniques to derive HSUVs considered in 
NICE appraisals 
by HSUV technique and level of influence 
Patient 
evidence 
    
Generic 






























Asfotase alfa   ≈    
Eculizumab ≈     +++ 
Patisiran ≈     +++ 
Voretigene   ≈    
Cerliponase   ≈    
Elosulfase alfa      +++ +++ 
Ataluren    ++   
Migalastat ≈     +++ 
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Eliglustat  ++    +++ 
Strimvelis    ++   





















Inotersen ≈      






[=antibiotics]  ≈    +++ 
Nintedanib ≈     ++ 
Lumacaftor–
ivacaftor  ≈     
Mepolizumab  +++     
Obeticholic acid    ++   
Holoclar   ++     
Pirfenidone*        
Darvadstrocel   ≈    
Nusinersen  ≈     
Letermovir ≈     +++ 
Lanadelumab +++      
Legend: HSUV: Health State Utility Value; NICE: National Institute for Health and Care 
Excellent; PRO: Patient Reported Outcome; PROM: Patient Reported Outcome Measure  
*No HSUV results were considered as this is a re-assessment and no new QoL evidence 
was provided  
+++ Accepted – HSUV results / patient evidence were influential in the final decision 
++ Not commented - HSUV results / patient evidence were reported and suggested some type of 
benefit, but no discussion about these results was reported – assumption is that they are likely to 
have influenced the decision 
≈ Uncertain - HSUV results were reported, but were considered uncertain  
 
The detail and summary of the individual appraisals are summarised in Table 4. Seven treatments 
used EQ-5D, two of which collected EQ-5D 3L in trials and the remaining collected EQ-5D 5L 
(mapped to 3L) or foreign EQ-5D datasets converted using the UK tariff. In one case, the HSUVs 
included in the model were considered acceptable by the TA Committee (lanadelumab). For mannitol, 
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the generic Health Utility Index Mark 2 (HUI2) was used to derive HSUV estimates. Even if EQ-5D 
would have been preferred, the HUI2 was accepted by the relevant committee. For all remaining 
cases, a number of issues were raised by the relevant committees, which included benefits 
(eculizumab, migalastat) or long-term effects not captured (letermovir), measure insensitive to change 
(nintedanib), uncertain duration (patisiran), or possible implausible health states (inotersen).  
Mapping was used in six cases, in one of which (lumacaftor-ivacaftor) the applicant developed a new 
algorithm, while in the others published functions were used. Source measures included lung function 
and pulmonary exacerbation (lumacaftor–ivacaftor), SF36 (eliglustat), PedsQL (nursinersen), CFQ-R 
(colistimethate sodium and tobramycin DPI), SGRQ (mepolizumab) and visual acuity (holoclar); all 
were converted to EQ-5D-3L. The results were considered acceptable in only one case 
(mepolizumab), or not commented on (likely acceptable) in two cases (eliglustat, holoclar). The issues 
raised regarding the remaining cases included: ceiling effects and little change captured even though 
it was collected in the largest existing cystic fibrosis trial (lumacaftor-ivacaftor), limited face validity 
resulting in expert elicitation being used to estimate the HSUVs (nusinersen), or limited 
methodological approach (colistimethate sodium and tobramycin DPI). 
Vignettes were used in five cases. Reasons for their use over more conventional approaches included 
a lack of correspondence between QoL data collected in the clinical trial and model health states 
(cerliponase), lack of negative values when deriving the PedsQL being considered unrealistic 
considering the condition’s severity (cerliponase), or QoL data not collected in trial (darvadstrocel, 
burosumab, voretigene). The health states were developed by patient and clinical experts 
(voretigene), or only clinicians (cerliponase, asfotase alpha, burosumab). Respondents included 
clinicians (voretigene, cerliponase, asfotase alpha, burosumab), or patients and public 
(darvadstrocel). The QoL measure included was EQ-5D-5L (cerliponase, asfotase alpha, burosumab), 
and HUI2 and EQ-5D (voretigene).  
 




Table 4. Use and influence of HSUVs in NICE TA and HST appraisals of non-oncology rare disease treatments (n=23)  
MEDICINE 
Generic name, indication 
HSUV 




Atypical haemolytic uraemic 
syndrome 
EQ-5D 
- all benefits not captured due to lack of data  
- ERG's HSUV lower than manufacturers (10 versus 25 QALYs) 
=> in both cases, substantial increase in QoL recognised 
Restrict - monitoring and stopping rules 
 
Cost-consequence model ~10-25 QALYs  
=> QoL underestimated due to lack of data 





EQ-5D: 5L mapped to 3L 
=> uncertain assumptions around HSUV, duration of treatment 
benefit 
 
HSUV after stopping treatment 
- uncertain evolution after stopping  
=> little effect on ICER  
 
HSUV carer 
- estimates revised to align with inotersen  
=> considered acceptable 
 
HSUV adverse events (gastro-intestinal, GI) 
- possible overlap with impact captured in EQ-5D  
=> value between manufacturer's estimate and no disutility  
=> scenario analysis using pessimistic GI disutilities 
~£125k/QALY 
 
Benefits not captured: ability to work, carry out daily activities, 
more active family and social life, maintain independence and 
dignity 
 List - commercial agreement 
 
~£80-125k/QALY 
=> no QALY weighing (~9.16 QALYs) 
=> ICER acceptable due to additional factors 
(severity, rarity, size of health benefits, benefits not 
captured, innovativeness, impact on carers) 





Generic name, indication 
HSUV 




Inherited retinal dystrophies 
(caused by RPE65-mediated 
IRD) 
Vignettes 
- implausible lowest health state [worse than death (-0.04 )] 
given patients confirmed adapting to disease 
- few clinicians involved in development 
- focus of clinicians focus on vision loss rather than QoL 
=> possible underestimation of QoL 
=> EQ-5D more appropriate due to focus on QoL (and not vision 
loss) 
 
TTO (published literature) 
- not robust, good complement to vignettes 
=> HSUV to fall between vignettes (company) and TTO (ERG) 
 
HSUV adverse events 
=> suitable, small effect on ICER 
 
HSUVs carers (published literature) 
=> only children included (adults excluded) 
List - commercial agreement 
 
ICER range £114,956 (company)-£155,750 (ERG) 
=> 1.2 QALY weight (QALY gains 12.1-17.7) 
Cerliponase 
Nuronal ceroid lipofuscinosis 
type 2 
PedsQL 
- Trial QoL data not used as HSUVs unavailable for all model 
health states  
=> preference for trial data, but recognition that possibility of 
negative values excluded, unrealistic given the severity of 
disability  
 
Vignettes/EQ-5D (5L mapped to 3L) 
- validation of vignettes and completion of EQ-5D 5L by clinical 
experts. 5L mapped to 3L 
- issues with robustness: additional elements such as pain and 
frequency of seizures included, but their association to motor 
and language scales defining health states unclear 
List - Managed Access Agreement 
 
ICER not specified, 3.0 QALY weight 





Generic name, indication 
HSUV 
Technique, appraisal  
DECISION 
ICER, reasons 
=> neither source of data sufficiently robust, suggesting lack of 
correspondence between vignette and model health states 
=> EQ-5D 3L mapped to HSUVs using vignettes considered, 
given no alternative data 
 
HSUV carers/siblings  
=> disutilities included, but 30 years considered to better reflect 
real life compared to life long  
Elosulfase alfa 
Mucopolysaccharidosis type IVa 
Various approaches and sources 
Issues around capturing QoL: 
- QOL rarely collected in trials, as challenging particularly for 
children (e.g. recollection of how they felt before treatment) 
- potential issue around questions: it's not about the activities 
they can do post-treatment, but about how they feel 
=> EQ-5D not collected in trial, limited evidence on QOL  
=> lack of developed/validated methods 
=> impact of adverse effects on QoL not included 
=> treatment improves QOL and HSUV increment considered 
appropriate 
=> uncertainty remains in HSUV modelled 
List - Managed Access Agreement + commercial 
agreement 
 
Cost-consequence model: limited impact on 
incremental QALYs 
 
QoL not appropriately captured due to challenges in 
measuring relevant effects and collecting data from 
children. No QoL measures collected in trials 
Ataluren 
Duchenne muscular dystrophy 
HSUV scoliosis and carers (published literature) 
- uncertainty around scoliosis not occurring after puberty (model 
assumption), or applying different HSUVs after loss of walking. 
Company's assumption: QOL linked to ability to walk greater 
since loss of walking would occur later. Clinical experts 
commented plausibility if loss is in upper limb muscle strength 
when ability to walk is lost, for which no evidence was presented  
=> unreasonable to assume different HSUVs across treatment 
group once ability to walk is lost given no evidence  
List - Managed Access Agreement  
 
Managed Access Agreement to capture carer HSUV 
using EQ-5D and Child Health Utility 9D  
 
Cost-consequence model ~2.389-8.562 QALY gains 
 
Wider benefits: indirect costs/benefits (ability to work 
of carers, decrease in out-of-pocket costs) 





Generic name, indication 
HSUV 





EQ-5D (questionnaire, Dutch cohort study with UK tariff) - 
enzyme replacement therapy and complications 
(comparator) 
- to measure disutility of patients undergoing enzyme 
replacement therapy 
- similar HSUV as for end-stage renal disease, stroke, heart 
complications 
- patients/clinicians emphasised major impact on QoL 
=> uncertain disutility values        
 
HSUV infusion (DCE)  
- 506 people from UK general population 
- HSUV infusion > HSUV complications 
=> not comparable since different methods used (uncertain face 
validity) 
=> patient input: recognition of added benefit of migalastat over 
ERT infusion (convenience from oral administration) 
=> decreasing infusion-disutility by 50% decreased QALY gains 
(from 0.98 to 0.34 incremental QALYs) 
Restrict - if ERT + patient access scheme 
 
Confidential cost-consequence model  
 
Miglastat considered to have similar benefits 
compared to ERT, with the main advantage of oral 
administration (patient input). Main concern about 
adherence with oral administration. Main driver of 
model infusion disutility 
Eliglustat 
Gaucher disease 
SF36 mapped to EQ-5D (published algorithm)  
 
HSUV adverse events  
- HSUV decrements applied  
 
HSUV oral administration 
- HSUV increment (0.12) based on preference for oral 
administration (vignette commissions by manufacturer) 
=> too high, ERG's estimate of 0.05 more plausible 




Model driven by QoL (mode of administration) 





Generic name, indication 
HSUV 







- 9 clinical experts completing EQ-5D for each level of severity 
(6MWT) 
=> reasonable face validity (suitability of measure in capturing 
concept of interest) 
=> not collected in trials 
- health states in the Markov model defined based on severity 
levels of 6MWT that, however, may not capture all the relevant 
symptoms 
=> measure accepted due to lack of available evidence 
=> HSUV for most severe health state very low (0.23), 
potentially overestimating benefits (more space for HSUV gain) 
=> lack of correspondence between vignettes and model health 
states 
 
EQ-5D (European patient survey) 
=> aligned with values in vignette study 
List - Managed Access Agreement + commercial 
agreement 
 
Cost-consequence model ~14-25 QALYs 
 
HSUV considered to reasonably capture impact on 
QoL, risk of underestimation compensated by carer 
disutility not included in model 





Generic name, indication 
HSUV 







Trial QoL data not included in model because limited  
 
HSUV QoL (published literature - no detail) 
- Full health HSUV from general population 
=> since no data on long term effect, these were explored within 
sensitivity and scenario analyses. The committee agreed lower 
values should be used 
 
HSUV intravenous immunoglobulin (IVIG) or severe 
infections  
- ERG: 0.75 HSUV included  
- plausibility confirmed by clinical experts  
HSUV carer 
- improved fast after treatment  
- no approach to measure 
- to be considered qualitatively during deliberations 
List 
 
£12-120K/QALY (14.0-19.6 QALY gained) 
 




- 6 clinicians value QoL of patients with XLH aged 18, 40 and 60 
years using EQ-5D 5L 
- some missing data, company inferred 1 for healed health 
states 
- scored by clinicians not patients, not from trials  
=> approach deemed appropriate (in absence of alternatives), 
but highly uncertain 
 
HSUV carer (literature) 
- published literature on people with limited mobility 
=> acceptable, not robust 
List - Managed Access Agreement + commercial 
agreement 
 
£113-£150K/QALY (5.52-15.99 QALYs gained) 
 
Most/less conservative assumptions 
included/excluded carer disutility (and different 
stopping ages) resulting in ICERS ranging from £112-
149k/QALY. Unclear to what extent variation due to 
inclusion/exclusion of carer disutility 





Generic name, indication 
HSUV 






EQ-5D (Brazilian registry converted with UK tariffs, source 
model HSUVs) 
- modelling of values from dataset with a number of 
assumptions, e.g. cap to ensure HSUVs do not exceed the 
general population 
=> model could generate implausible health state classifications 
=> not ideal, but acceptable, considered uncertain 
 
HSUV carer 
- 1 in stages 1-2, 2 in stage 3 
List - commercial agreement 
 
£96,697-£150,636/QALY (no QALY weighing) 
 
HSUV values did have some effect on model, but 
generally uncertain 
=> unclear if driving the model 





- mean disutility at baseline (0.988), average change at each 
timepoint added to baseline to calculation HSUV for each health 
state  
=> HUI2 baseline considered high given multiple comorbidities 
=> EQ-5D measure preferred  
=> difficulty to value health states in chronic conditions. 
Standard method of using general population's valuation of QoL 
descriptions to generate HSUVs appropriate 
 
HSUV lung transplant and pulmonary exacerbations 
(literature) 




Model changes with extension of life, little with 
changes in QoL 
- patients confirmed treatment improved QoL, 
considered important  
=> HSUVs values very uncertain  





Generic name, indication 
HSUV 
Technique, appraisal  
DECISION 
ICER, reasons 
Colistimethate sodium and 
tobramycin dry powders for 
inhalation (DPI) [=antibiotics] 
Pseudomas lung infection in 
cystic fibrosis 
HSUV Colistimethate sodium DPI  
CFQ-R mapped to EQ-5D 
=> no preference-based model considered a methodological 
limitation 
Health utility study linking EQ-5D responses to FEV% 
health states  
=> issue around establishing relationship, but considered more 
appropriate compared to manufacturer's model (mapping) 
 
HSUV Tobramycin DPI (patient input) 
=> DPI to improve QoL in terms of speed and adherence 
compared to nebuliser 
List - Patient Access Scheme  
 
Drivers of cost-effectiveness model: cost of 
interventions and their comparators, QALY 
gains/losses 
 
Colistimethate sodium DPI: small QALY loss (based 
on HSUV/QoL evidence) but substantial cost savings 
over nebuliser 
 
Tobramycin DPI: dominant - small QALY gain (no 
HSUV/QoL evidence, based on patient input) and 
cost saving (DPI dominated nebuliser)  
Nintedanib 
Idiopathic pulmonary fibrosis 
EQ-5D (trial) 
- model based on predicted FVC changes and rate of 
exacerbations 
 
HSUV adverse events 
- serious gastro-intestinal events, rash related events 
=> model did not include diarrhoea-adverse events as not 
severe and affected a small proportion of patients  
=> committee did not agree, and considered it to affect QoL 
 
HSUV exacerbations   
=> possible gains in QOL not captured in QALY (tolerability 
profile, reduced dosing frequency) 
=> lack of sensitivity to change 
Restrict - clinical parameters + Patient Access 
Scheme 
 
Dominant over pirfenidone (survival equal, 
differences in QALYs) 
 
Committee recognised that additional impact on QoL 
not captured in model 





Generic name, indication 
HSUV 





HSUV QoL (multivariate mixed model) 
- repeated regression analysis to model relationship between 
EQ-5D, lung function and pulmonary exacerbations in trials  
- no change in EQ-5D + little opportunity to demonstrate 
improved QoL due to ceiling effect 
- clinical experts state that EQ-5D capture most important 
effects in cystic fibrosis 
- committee tested model with values from another study 
(Lancaster) that better captured changes in QOL using EQ-5D 
in patients with similar levels of severity, resulting in increased 
ICER by ~65K/QALY 
=> HSUV not captured adequately, uncertainty in model 
=> however, trial data used, which is the biggest trials 
conducted in cystic fibrosis to date 
 





Model mostly driven by changes in life years gained 
 
When HSUVs from other study were used 
(Lancaster), ICER increased by 65K 
Mepolizumab 
Severe refractory eosinophilic 
asthma 
SGRQ (MENSA trial) mapped to EQ-5D  
- mapping algorithm based on population with chronic 
obstructive pulmonary disease 
- used as baseline value, adjusted due to differences between 
treatment arms and ages 
=> considered acceptable 
 
EQ-5D (DREAM trial) 
- values adjusted for differences in baseline utilities values 
=> baseline adjustment considered appropriate 
 
HSUV exacerbation  




Little effect of QoL on ICER. EQ-5D mapped from 
SGRQ considered in model, EQ-5D values from 
DREAM trial accounted for in the interpretation of 
QoL impact. 
Drivers included exacerbation rates, age-related 
mortality estimates and attrition rates 





Generic name, indication 
HSUV 
Technique, appraisal  
DECISION 
ICER, reasons 
- mid-point between trial data and published value  
=> little change when using different disutility values, approach 
acceptable 
Obeticholic acid 
Primary biliary cholangitis 
No HSUVs data collected in trials  
 
Published literature and expert assessment 
- Chronic Hepatitis C and previous Technology Appraisal 
reports 
=> some issues raised, but accepted  
List - Patient Access Scheme 
 
~£33K/QALY, additional factors considered: ICER 
underestimated in trial due to lack of adjustment up to 
recommended dose in some patients + innovative 
nature + potential to return to normal life + opportunity 
cost of liver transplant on other patients needing it  
Holoclar  
Limbal stem cell deficiency after 
eye burns 
Mapping (HSUV visual acuity) 
- combination of visual acuity in both best and worst seeing 
eyes 
- published mapping algorithm  
=> model did not capture:  negative effect on donor eye 
=> if donor disutility captured, ICER likely to decrease 
 
HSUV from pain, burning, photophobia  
-  base case value attached to presence of moderate or severe 
pain/burning/ photophobia derived from EQ-5D 3L tariff and 
uses the level 2 and 3 decrements of -0.123 and -0.386 
respectively. Alternative values of no decrement and that 
derived from the general population SG method of -0.291 for 
Restrict - subgroups and 1 eye + Patient Access 
Scheme 
 
£6,948-£30,415-£42,139/QALY (lower values with 1 
eye) 
 
Best plausible ICER was above £20K/QALY (includes 
ERG's estimate of disfigurement decrement). The 
committee accepted that if the model had considered 
a negative impact on donors, it would most likely be 
cost-effective  
=> accepted for reimbursement 





Generic name, indication 
HSUV 
Technique, appraisal  
DECISION 
ICER, reasons 
both moderate and severe were used  
 
Disfigurement HSUV 
- Bespoke standard gamble exercise performed by 520 UK 
participants who were presented with various clinical scenarios 
describing moderate to severe limbal stem cell deficiency, 
including an image of a patient's eye with this condition showing 
the extent of the disfigurement typically present 
- estimated at 0.308 
=> applied from non-reference case methods and likely to be 
exaggerated  
=> patients with one eye may prioritise impact of disfigurement 
over visual acuity, and those with two eyes affected may 
prioritise visual acuity over disfigurement 
=> cataract disutilities  considered more appropriate estimate of 
impact on QoL 
 
=> HSUV of 0.840 as base case for visual acuity and HSUV 
decrement of 0.140 for disfigurement 
Pirfenidone  
Idiopathic pulmonary fibrosis 









Generic name, indication 
HSUV 






=> considered robust given significant number of participants 
(n=835 general public and n=162 patients with Crohn’s disease) 
=> reliable estimates of HSUVs 
=> vignettes used considered appropriate (even if EQ-5D not 
collected in trial), also aligns with values in literature 
 
=> HSUVs in some heath states might be too low, and that 






Very uncertain model. HSUVs may have some 
influence on ICER levels 





Generic name, indication 
HSUV 




Spinal muscular atrophy 
HSUV expert elicitation 
=> not based on formal elicitation methods (may differ if other 
clinicians were to redo exercise) 
=> questions asked to clinicians not available, making it difficult 
to interpret 
=> health states based on motor function may not have 
captured QOL impact, differences in HSUVs between health 
states small 
 
HSUV PedsQL mapped to EQ-5D 
- published algorithm for later onset, and HSUVs adapted for the 
early onset model based on assumed correspondence of health 
states (values confidential) 
=> limited face validity, not considered appropriate 
 
=> challenge in babies and children 
=> HSUV techniques not ideal, results highly uncertain 
 
HSUV carer  
- best health state based on general population HSUV, worse 
health state based on cross-sectional study of SMA patients, 
adjusted for each health state 
- equal transitions between these 2 points  (values confidential) 
=> based on assumptions and not on evidence 
=> key driver in ICER (better ICER for later onset, worse for 
early onset due to carer disutility "saved" from early death - 
seen as "perverse" effect) 
=> to be included, but highly uncertain 
 
Disutility due to bereavement  
- applied as -0.04  
Restrict - Types 1,2,3 + Managed Access 
Agreements  
 
ICER not specified 
 
Key driver in models - may impact differently early 
and late onset models: carer disutility (highly 
uncertain, difficult to quantify), resource costs  





Generic name, indication 
HSUV 





EQ-5D-3L (published literature) 
- Long term disutility associated with haematopoietic stem cell 
transplant derived from a mix of EQ-5D 5L and 3L values from 
two published studies 
- ERG proposed alterative approach based on difference 
between mean HSUVs of patients in trial (PN001, 48 weeks) 
and the general population from another study 
=> ERG approach preferable 
List - commercial agreement 
 
<£24,269/QALY likely <£20,000/QALY 
 
ICER likely to decrease due to QoL not captured in 




Committee accepted alternative approach to EQ-5D-5L 
(recognised as insufficiently sensitive).  Published study used to 
derive HSUVs, which collected EQ-5D-5L about health state 
today and health state during last attack  




QALY gains small relatively to costs, ICER could 
change with different clinical scenarios 
*No HSUVs were reported for one treatment (pirfenidone) given it was a re-assessment; therefore, it was excluded from this analysis, which focuses on the 23 
remaining treatments. 
Legend: HSUV: health state utility values; QALY: quality-adjusted life years gained; ICER: incremental cost-effectiveness ratio; EQ-5D: EuroQol-5 Dimension; 
EQ-5D-3L: EuroQol-5 Dimension-3 Level; EQ-5D-5L: EuroQol-5 Dimension-5 Level; GI: gastro-intestinal; QoL: quality of life; ERG: Evidence Review Group; 
IRD: Inherited retinal dystrophies ; TTO: time-trade off; PedsQL: Paediatric Quality of Life Inventory - Parent Report for Toddlers; DCE: discreet choice 
experiment; ERT: enzyme replacement therapy; 6MWT: 6-minute walk test; IVIG: intravenous immunoglobulin; HUI2: Health Utility Index Mark 2; DPI: 
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A number of issues were raised about the vignettes. For voretigene, poor convergent validity between 
EQ-5D and HUI2 and preference for EQ-5D (considered to better capture overall QoL over HUI2) 
were highlighted. For alfotase alfa, trial data would have been preferred over vignettes by the 
appraisal committee; however, QoL results from the vignette were compared to results from a patient 
survey and considered aligned. Additionally, given the health states were based on the surrogate 
outcome “six-minute walking test” (6MWT), all of the relevant symptoms that would produce lower 
HSUVs in the more severe states may not have been captured (likely underestimate). The HST 
Committee was also concerned with clinicians responding to the vignettes instead of patients 
(burosumab). Furthermore, there was concern about the uncertain robustness of the vignettes given 
an unclear association of other elements (e.g., pain) to health states (cerliponase). 
Published literature was used in three cases. This was because QoL was not measured in the trials 
(strimvelis, obeticholic acid) or the available mapping algorithm was conducted on a healthy 
population and thus unsuitable (ataluren). No detail on the published literature was provided for 
strimvelis and ataluren, whereas for obeticholic acid, values from an analogue disease (Hep C) were 
used.  
In one case (elosulfase alfa), HSUVs were derived by converting improvement in 6MWT and forced 
vital capacity (FVC) collected in natural history studies and combining these with the correlation 
observed between 6MWT, FVC and QoL from the patient and families survey. For each additional 
benefit reported by patients not captured in 6MWT or FVC, an HSUV increment was derived from the 
literature. The HST Committee highlighted that the data were not collected within a trial but 
recognised the challenges in collecting QoL data from children alongside the lack of validated 
PROMs.  
Use and influence of PRO evidence and HSUV estimates in HAS, G-BA and ZIN appraisals  
Comparing the appraisal of PRO evidence by NICE with those by ZIN, G-BA and HAS, a number of 
observations arose (Table 5). First, a proportion of the appraisal reports did not include any detail 
about QoL evidence (38% for ZIN, 61% for HAS, and 16% for G-BA). Second, a vast majority of those 
that did report QoL data were deemed inconclusive. The main reasons were the lack of statistical 
significance (ZIN, HAS, G-BA), the exploratory nature of the evidence, e.g. secondary endpoint 
(HAS), the non-inclusion of a hierarchical test (HAS), the lack of validated or non-clinically relevant 
endpoint (G-BA). Third, in the few cases when QoL was considered to be improved by treatment in 
one country, a different outcome was determined in the other countries. Only one treatment appraised 
by HAS (inotersen) was considered to provide a moderate improvement in QoL, as it was one of the 
trial’s co-primary endpoints; whereas no meaningful clinically relevant change was recognised by 
NICE and G-BA. Two treatments appraised by G-BA, patisiran and lanadelumab, were considered to 
provide some benefit as they were both validated and clinically relevant endpoints. For ZIN, it was 
unclear whether the PRO evidence had any influence on the decisions and the HSUVs appraised for 
three treatments were considered very uncertain. 




Table 5. Use and influence of PRO evidence in HAS, G-BA and ZIN appraisals of non-oncology rare disease treatments 
MEDICINE 
Generic name - indication 
PRO EVIDENCE AND APPRAISAL  
HAS (France) G-BA (Germany) ZIN (Netherlands) 
Asfotase alfa  
Paediatric-onset 
hypophosphatasia 
no details provided no trial QoL data, no conclusion  no details provided  
Eculizumab  
Atypical haemolytic uraemic 
syndrome (aHUS) 




no details provided  Norfolk QoL-DN: statistically improved; validity and 
reliability confirmed; possible bias from higher 
missing values after 18 months in control group; 
no MID, effect size’s hedges calculated for 
dossier; clinically relevant difference 
NA 
Voretigene  
Inherited retinal dystrophies 
VFQ: not demonstrated. Secondary 
judgment criterion, no hierarchical 
test  
VFQ: unsuitable. Transferability and MID from NEI 
VFQ-25 to new VFQ inappropriate 
Vignettes, EQ-5D-5L, HUI3: 
not adequately collected 
Cerliponase  
Nuronal ceroid lipofuscinosis 
type 2 
PedsQL, CLN2-QoL, EQ-5D 5L: 
exploratory consideration of QoL, 
stabilisation in treatment group 
versus degradation in natural history 
data 
PedsQL: no benefit in QoL recognised due to lack 
of comparative data and clinical relevance of 
change 
 
CLN2-QoL: not considered as no data on its 
development (by company) and validation 
provided 
NA 





Generic name - indication 
PRO EVIDENCE AND APPRAISAL  









no details provided  PODCI: not statistically significant. Quality and 
patient relevance not demonstrated due to lack of 
information 




no details provided  SF-36: inconclusive SF-36: inconclusive 
Eliglustat  
Gaucher disease 
no details provided  BPI, FSS, SF-36: no significant differences SF-36, BPI, FSS, DS3: 
clinically relevant and crucial, 





NA NA NA 
Burosumab for X-linked 
hypophosphataemia 
SF-36, PROMIS: exploratory, not 
usable 
SF-10: lack of information on questionnaire 
development, restrictions in content validity, 





Norfolk QoL-DN: modest 
improvement as co-primary endpoint 
 
SF-36: not discussed 
SF-36: biased due to missing values 
 
Norfolk-DN: no valid MID based on hedge’s g, 
effects not clinically relevant. Statistically 
significant improvement, but not clinically relevant 
 
C-SSRS: not discussed  
NA 





Generic name - indication 
PRO EVIDENCE AND APPRAISAL  
HAS (France) G-BA (Germany) ZIN (Netherlands) 
Mannitol for cystic fibrosis no details provided  NA CFQ-R: no significant 
improvements. Overall effect 
around improving QoL and 
reducing pulmonary 
exacerbations 
Colistimethate sodium and 
tobramycin dry powders 
for inhalation (DPI) 
[=antibiotics]  
Pseudomas lung infection in 
cystic fibrosis 
no details provided  NA no details provided  
Nintedanib  
Idiopathic pulmonary fibrosis 
EQ-5D, EORTC QLQ-30, QLQ-LC13: 
no expected improvement 
G-BA/IQWiG 
EQ-5D VAS: statistically improved, benefit not 
proven given hedge’s g 
 
SGRQ: not discussed 
SGRQ: not clinically relevant  
Lumacaftor–ivacaftor 
Cystic fibrosis 




NA no details provided  no details provided  
Obeticholic acid for primary 
biliary cholangitis 
no details provided  PBC-40: validated measure. Responsiveness and 
MID not examined. Marginal change, but clinical 
relevance not determined 
PBC-40: no improvement  





Generic name - indication 
PRO EVIDENCE AND APPRAISAL  
HAS (France) G-BA (Germany) ZIN (Netherlands) 
Holoclar for limbal stem cell 
deficiency after eye burns 
NA no details provided  NA 
Pirfenidone  
Idiopathic pulmonary fibrosis 
no details provided  SGRQ, WHO QoL: no proof of added benefit EQ-5D, SGRQ:  from 
published paper. Unclear 
benefit as baseline values and 
validation difficult to verify 
Darvadstrocel  
Crohn’s disease 
Van Assche Score, IBDQ: 
exploratory secondary endpoints, no 
change captured 
IBDQ: not designed or validated for target 




Spinal muscular atrophy 
PedsQL: not possible to quantify QoL 
benefit due to low response rates 
PedsQL: QoL not demonstrated. Caregiver 
experience included 
PedsQL mapped to EQ-5D 
Letermovir  
Cytomegalovirus 
EQ-5D-3L: unsuitable, used to derive 
HSUVs for different health states 
rather than change in QoL 
associated with an illness 
EQ-5D, FACT-BMT 
FACT-BMT considered validated in patient 
population 
not details provided  
Lanadelumab for hereditary 
angioedema 
AE-QoL: unusable as exploratory 
endpoint 
AE-QoL: statistically improved, considered 
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Impact on carers 
Eighteen of the treatments were considered to have an impact on carers (Table 1), whereas evidence 
on carer impact was considered for only nine of these by NICE (8 HST and 1 TA). Impact of disease 
and treatment on carers was considered either qualitatively or quantitatively through HSUVs. In the 
former case, the relevant committees discussed the burden on carers during the deliberative process 
(mepolizumab, strimvelis, asfotase alfa), and in other cases, considered evidence from patient/carer 
surveys (eculizumab, elosulfase alfa). In the latter cases, HSUVs were derived from various sources 
(e.g. published literature, number of carers affected, report on challenges from living and caring for a 
sick child, or cross-sectional surveys). Some of the HSUVs submitted were changed so as to better 
align with previous appraisals (patisiran), to only include HSUVs for children (voretigene), to reflect a 
shorter timeframe (cerliponase), or to reflect a different number of carers (ataluren). In four of these 




This study explored the appraisal of QoL in all the non-oncology rare disease treatments considered 
by NICE. It is the first study of this type, which furthers our understanding of the nature of QoL 
evidence and the nuances of its use in HTA of rare disease treatments.  
Our results primarily enable a better understanding of whether the QoL evidence was actually 
considered. The vast majority of conditions investigated, particularly in NICE’s HST programme, are 
life-threatening and/or debilitating.  For all of the treatments investigated, their added benefit was also 
considered to improve QoL. Measuring their impact on QoL is therefore critical in determining their 
added benefit, particularly for those treatments aiming solely to improve QoL. This, however, is not 
reflected in our results. PRO evidence was not reported for a large number of treatments across all of 
the study countries, and when reported, most of the PROMs and results were not discussed (and 
therefore we assume not accounted for). In the other study countries, no PRO evidence was reported 
in 16%, 38% and 61% respectively in Germany, the Netherlands and France. It was not clear from the 
appraisal reports why this evidence was not reported nor accounted for. When PRO evidence was 
reported, it was limited to one or two PROMs (versus more in the NICE reports).  
Overall, a large amount of QoL data was collected, but these data were barely reported or referred to 
in the appraisal reports across the different study countries. However, the 28 different PROMs 
identified and collected in the trials are most likely covering concepts important for patients [5].  Their 
lack of use points either to a loss of valuable information on the patient perspective, issues in 
capturing meaningful change in rare diseases, or issues in accounting for all of these PROMs within 
the HTA approach adopted. Results illustrate that different QoL evidence would be considered 
depending on the HTA approach.  For cost-effectiveness oriented approaches, HSUVs are 
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considered within the incremental cost-effectiveness ratio and are derived from PRO data using 
indirect techniques (e.g. generic preference-based instruments, mapping), or measured directly from 
patient responses using direct techniques (e.g. time-trade-off) [44]. In countries with an added clinical 
benefit assessment approach, the PRO data would be considered and interpreted as is without being 
derived into a numerical HSUV. To help with the comparability and interpretation of the PRO data, 
generic PROMs are often preferred. Consideration should therefore be given to how this information 
could be better used in HTA. This could be achieved through greater involvement in early multi-
stakeholder dialogues and early scientific advice to better align across HTA bodies and agree on what 
QoL evidence would be accepted, and a greater acceptance of registry data to leverage early on data 
on natural history on the disease.  
Second, our results enable a better understanding of whether the QoL evidence actually 
considered was impactful. Results point to a limited influence of PRO evidence in general. In the 
NICE appraisals, this was because QoL is mainly measured by HSUVs used in the economic models. 
PRO evidence was considered to support the interpretation of HSUVs included in the model in one 
case, and potentially in a few other cases; but overall, its influence was fairly limited. Just over 1/3 of 
the HSUVs were accepted, even if, in some cases, they were recognised as not ideal. In the 
remaining cases, the HSUVs were highly uncertain and in most cases the relevant committee 
recognised that all benefits were not captured. In these cases, interpretation was informed by 
information from patient and clinicians in four cases, and a patient survey in one case.  
Only three disease-specific PROMs were reported, but their consideration had a limited influence on 
the decision and in only one case, it was mapped to derive HSUVs. This confirms the issue of a lack 
of validated disease-specific preference-based PROMs and their conversion into HSUVs through 
mapping [8, 45, 46].  Disease-group PROMs were more frequently used and may constitute a suitable 
alternative for rare diseases; however, their influence was also limited. A similar situation was seen 
around the use of symptom-specific PROMs. By contrast, there were a number of cases where the 
relevant committees recognised that the QoL evidence did not capture the full range of dimensions 
important to patients. These related to improvements in QoL, such as the ability to return to work, to 
perform daily activities, to have a social life, to maintain independence and dignity, improving in 
walking, better tolerability profile, reduced dosing frequency, or improved patient choice, as well as 
decrements in QoL, such as the impact from relying on wheelchairs, or adverse events not captured. 
However, considering that many of these domains are typically covered in PROMs, the issue may be 
more around the lack of sensitivity of these measures rather than domains not being captured.  
In Germany and France, most of the PRO evidence was considered inconclusive due to the frequent 
lack of a statistically significant improvement and/or they did not meet the country-specific evidentiary 
requirements. In Germany, PROMs need to be validated and PRO evidence clinically relevant (based 
on a minimally important difference (MID)). However, a treatment failing to meet the MID criterion 
does not imply lack of improvement across all patients, where there may be some patients improving 
above the MID and others under [47]. This may be more frequent in heterogeneous and small patient 
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populations [48].  In France, the PRO endpoint should be a significant one (e.g. primary endpoint). In 
only one case in France and two cases in Germany was QoL considered improved, and this 
concerned different treatments. Similarly in the Netherlands, the PRO evidence was generally 
inconclusive and the HSUVs reported in three cases were considered very uncertain.  
Overall, findings suggest that a big proportion of the PRO evidence and HSUVs appraised are either 
not considered or provide inconclusive uncertain outcomes. The main contrast between NICE and the 
other countries is their willingness to account for other forms of evidence, such as patient surveys or 
expert input to provide additional and complementary information on QoL impact. They also appear to 
be more flexible when interpreting QoL evidence, e.g. in recognising that all benefits are not captured 
by the measures used, and account for that when making their decisions. 
We then tried to understand whether the issues highlighted by the relevant committees related 
to nature of rare disease treatments. One main distinction seen in NICE’s HST Programme is a 
greater likelihood of treatments targeting children/infants or treating heterogeneous and/or multi-
systemic conditions.  In the 15 NICE appraisals affecting children, only three considered children-
specific PROMs (PedsQL) and none considered any proxy-reported PRO evidence. This confirms the 
frequent lack of validated measures in children [10], but does not reflect the common reliance on 
proxy-reported data [9]. In only one case was the PedsQL mapped to EQ-5D, but results were limited 
and the challenges in collecting data from children recognised (together with another case).  
The extent to which it may be more difficult to capture meaningful and generalisable outcomes in 
heterogenous populations and conditions affecting multiple organs [9, 10, 49] was not entirely clear 
from the results. There were, however, cases where evidence on QoL was lacking to estimate the 
HSUVs required by the model (ataluren), to capture all relevant symptoms (asfotase alfa), or to deal 
with multiple co-morbidities (mannitol).  
Patient numbers for three HST treatments were small (an incidence of 1-7 patients/year in England), 
possibly resulting in uncertain aggregated results [9]. In one case (cerliponase), the HST Committee 
recognised an initial improvement in QoL based on PRO evidence. However, vignettes were used to 
derive HSUVs due to the lack of correspondence of PRO evidence with health states. The other two 
cases either did not report (asfotase alfa), nor collect (strimvelis) any PRO evidence, and published 
literature was used to derive HSUVs.   
No existing treatments were available for almost 60% of the 12 HST and 17% of the 12 TA treatments 
(in total, 9 of 24 treatments). Current standards of care for these diseases require multi-disciplinary 
specialised services and are considered burdensome for patients and their carers. They generally 
entail monitoring of disease, management of symptoms, complications or disability, and/or supportive 
care (e.g. counselling, occupational therapy, physiotherapy, social care, palliative care, etc.). This 
may create additional challenges in identifying the relevant domains of QoL to measure in the 
comparative arm [50].  
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Three quarters of the conditions appraised affect QoL of families and carers, and the treatments were 
considered to improve their QoL.  None of the PRO evidence collected and reported related to carer 
burden. However, the NICE Committees did account for the impact on carers either qualitatively or in 
cases where impact on carer’s QoL was collected within a patient and carer survey (eculizumab). On 
the other hand, carer HSUVs were estimated in only eight cases for which more than half the data 
were uncertain or inconclusive. This further emphasises the tendency for inconsistent inclusion of 
carer HSUVs and the variety of approaches used for their measurement [51]. There is a need for 
methodological guidance on when and how to include carer HSUVs in QALY and non-QALY 
approaches to HTA [52].  Considering that 80% of rare diseases affect children, and are often severe 
and disabling, including carer QoL is crucial in determining the added benefit of a new treatment.  
 
Limitations 
This study is not without limitations. First, it relies on information from a small number of appraisals, 
which is unavoidable given the small number of RDTs (excluding oncology treatments) considered 
each year. Secondly, it relies on official reports, which may not comprehensively depict the full 
appraisal process. This was more pronounced for some study countries that do not provide detail of 
their appraisal of the evidence. Based on expectations around transparency, we considered that the 
items documented in the HTA reports included the most important determinants of decisions. Further, 
there may have been some limitations relating to language barriers given the use of google translator 
for some of the countries. However, no inconsistencies across countries were identified that could 
indicate missing or misinterpreted information. Additionally, our document analysis was qualitative 
and as a result, we may have missed or misinterpreted some aspects leading to the decision. Given 
the complexity of some of these appraisals, it was challenging to identify explanations for some of the 
limitations highlighted, and how they related to the nature of rare diseases. However, we attempted to 
identify some possible explanations and examples on some of the implications. Finally, this study 
highlights some of the nuances in considering QoL evidence in rare diseases. It is possible that some 
of the same issues could arise in the HTA of more common diseases. Further research would be 
needed to compare the results from this analysis with those from a similar analysis of HTAs for 
common non-cancer treatments.  
 
Conclusions 
This study highlights some of the limitations and challenges in appraising PRO evidence and HSUVs 
to understand the impacts of a rare condition and treatments on QoL, and the influence of these 
aspects on determination of value. In many cases, PRO evidence did not have a major influence in 
HTA decisions, as it often did not demonstrate meaningful change or was inconclusive. The HSUVs 
were often very uncertain due to numerous reasons, such as being insensitive to change, ceiling 
effects, limited face validity, not capturing all domains important to patients, lack of long-term data or 
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methodological issues. This emphasises the need for improved development, testing, use and 
reporting of PRO evidence, and use of HSUVs that are better adapted to rare disease specificities, 
such as small sample sizes. HTA bodies would also benefit from greater flexibility in accepting less 
conventional techniques to derive HSUVs, for example, using vignettes, but there is a need to 
develop methodologies that support their robust development and application. Additionally, patient 
evidence, including patient surveys, focus groups, interviews, and expert testimony, have shown to be 
crucial for providing information about the burden of illness, treatment benefits including outcomes 
that matter most, and in supporting the interpretation of uncertain aspects of the QoL evidence 
considered important for the decision.  
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